Inclusion Criteria:

- Postmenopausal (no menstrual cycle in the past 12 months), because menstrual cycle
affects baseline expression of biomarkers such as Ki-67

- Diagnosed with incident, primary, invasive, ductal or lobular, or other epithelial
malignancy, clinical stage I or II, ER positive breast cancer

- No neoadjuvant endocrine therapy or chemotherapy

- No prior chemotherapy

- Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2

- Willing to avoid cruciferous vegetable intake during the study period (2 weeks)

- Demonstrate the ability to swallow and retain oral medication

- Subject or legal representative must understand the investigational nature of this
study and sign an Independent Ethics Committee/Institutional Review Board approved
written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

- Prior invasive breast cancer, prior mastectomy or breast radiation

- Current or recent use of reproductive hormone therapy, tamoxifen, aromatase inhibitor
or other estrogen inhibitors within the last 90 days, which may affect biomarkers

- Intolerance to broccoli/ITC-BSE taste

- Current ingestion of broccoli sprout extract, which may confound study results

- Current or recent treatment for any malignancy within the last one year, which may
affect biomarkers

- History of Crohn's disease, celiac sprue or other malabsorption syndrome which may
interfere with digestion and absorption of broccoli sprout extract